Your Messages Inbox
Your Article Summary
See Latest ArticlesAn Appraisal of Current Beliefs in the Design and Analysis of Clinical Trials for Antidepressant Drugs
Clinical Pharmacology & Therapeutics, 08/13/09
Santen G et al. – The results reveal that an increase in the frequency of visits does not increase statistical power, a skewed randomization for a placebo or comparator arm may decrease statistical power, and analysis of the percentage of responders should be avoided. CTS should become best practice in the optimization of study design. To date, no other statistical approach has enabled such comprehensive evaluation of the factors contributing to study failure in depression.
Related Articles
Increase In Long-term Antidepressant Drug Use, UK Study Reveals
ScienceDaily, 10/26/09
Relevance Score: 67%
Study reveals an increase in long-term antidepressant drug use
EurekAlert, 10/23/09
Relevance Score: 67%
Viagra for Women? Drug Developed as Antidepressant Effective in Treating Low Libido
ScienceDaily, 11/17/09
Relevance Score: 66%
The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets, 10/30/09
Relevance Score: 66%
New drugs for migraine
The Journal of Headache and Pain, 10/05/09
Relevance Score: 66%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09
Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09
Article Search
Sponsor